Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)-update 2012

European Journal of Human Genetics

Volumn 21, Issue 1, 2013, Pages 118-

  Rahner, Nils ^a   Steinke, Verena ^b   Schlegelberger, Brigitte ^c   Eisinger, Francois ^d   Hutter, Pierre ^e   Olschwang, Sylviane ^d  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d INSTITUT PAOLI CALMETTES   (France)

^e Institut Central des Hopitaux Valaisans   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; ADENOSINE TRIPHOSPHATASE; CELL ADHESION MOLECULE; DNA BINDING PROTEIN; EPCAM PROTEIN, HUMAN; G T MISMATCH BINDING PROTEIN; G-T MISMATCH-BINDING PROTEIN; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PMS2 PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR ANTIGEN;

ARTICLE; BIRTH; COLORECTAL CANCER; DIFFERENTIAL DIAGNOSIS; GENE DELETION; GENE DUPLICATION; GENE MUTATION; GENOTYPE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; LIFESTYLE; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; FEMALE; GENETIC SCREENING; GENETICS; METHODOLOGY; MUTATION; PREGNANCY; PRENATAL DIAGNOSIS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FEMALE; GENETIC TESTING; HUMANS; LIFE STYLE; MUTATION; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; PREGNANCY; PRENATAL DIAGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 84871255933     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2012.164     Document Type: Article

References (19)

1. Vasen HF, Watson P, Mecklin JP, Lynch HT: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116: 1453-1456.
2. Umar A, Boland CR, Terdiman JP et al: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261-268.
3. Loughrey MB, Waring PM, Tan A et al: Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer 2007; 6: 301-310.
4. Shia J: Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 2008; 10: 293-300.
5. Boland CR, Thibodeau SN, Hamilton SR et al: A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-5257.
6. Halvarsson B, Lindblom A, Rambech E, Lagerstedt K, Nilbert M: Microsatellite instability analysis and/or immunostaining for the diagnosis of hereditary nonpolyposis colorectal cancer? Virchows Arch 2004; 444: 135-141.
7. Grover S, Syngal S: Genetic testing in gastroenterology: Lynch syndrome. Best Pract Res Clin Gastroenterol 2009; 23: 185-196.
8. Niessen RC, Hofstra RM, Westers H et al: Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer 2009; 48: 737-744.
9. Etzler J, Peyrl A, Zatkova A et al: RNA-based mutation analysis identifies an unusual MSH6 splicing defect and circumvents PMS2 pseudogene interference. Hum Mutat 2008; 29: 299-305.
10. Lamberti C, Mangold E, Pagenstecher C et al: Frequency of hereditary non-polyposis colorectal cancer among unselected patients with colorectal cancer in Germany. Digestion 2006; 74: 58-67.
11. de la Chapelle A: The incidence of Lynch syndrome. Fam Cancer 2005; 4: 233-237.
12. Tresallet C, Brouquet A, Julié C et al: Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome. Int J Cancer 2012; 130: 1367-1377.
13. Vasen HF, Möslein G, Alonso A et al: Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007; 44: 353-362.
14. Burn J, Gerdes AM, Macrae F et al: Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378: 2081-2087.
15. Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-618.
16. Schmeler KM, Lynch HT, Chen LM et al: Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006; 354: 261-269.
17. Celentano V, Luglio G, Antonelli G et al: Prophylactic surgery in Lynch syndrome. Te c h Coloproctol 2011; 15: 129-134.
18. Stoffel E, Mukherjee B, Raymond VM et al: Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 2009; 137: 1621-1627.
19. Krausz C, Quintana-Murci L, McElreavey K: Prognostic value of deletion analysis: what is the clinical prognostic value of Y chromosome microdeletion analysis? Hum Reprod 2000; 15: 1431-1434.